Weekly irinotecan and cisplatin in advanced non-small cell lung cancer: A multicenter Phase II study

Clinical Cancer Research

Volumn 7, Issue 1, 2001, Pages 68-73

  Jagasia, Madan H ^a   Langer, Corey J ^a,b   Johnson, David H ^a   Yunus, Furhan ^a,c   Rodgers, John S ^a,d   Schlabach, Larry L ^a,e   Cohen, Alan G ^a,f   Shyr, Yu ^a   Carbone, David P ^a   DeVore, Russell F ^a  

^a VANDERBILT UNIVERSITY   (United States)

^b FOX CHASE CANCER CENTER   (United States)

^c Methodist Le Bonheur Healthcare   (United States)

^d WEST VIRGINIA UNIVERSITY   (United States)

^e Erlanger Medical Center   (United States)

^f SAINT THOMAS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; IRINOTECAN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD TOXICITY; BRAIN METASTASIS; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0035135474     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Chemotherapy of lung cancer
2. Non-small cell lung cancer. Part I. Biology, diagnosis, and staging
3. Lung cancer practice guidelines: Lessons learned and issues addressed by the Ontario Lung Cancer Disease Site Group
4. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I
5. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin
6. Arrest of replication forks by drag-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin
7. DNA topoisomerases-enzymes that catalyse the breaking and rejoining of DNA
8. DNA topoisomerases
9. Effects of CPT-11 in combination with other anti-cancer agents in culture
10. Enhanced antitumor efficacy of a combination of CPT-11, a new derivative of camptothecin, and cisplatin against human lung tumor xenografts
11. Inhibition of cis-diamminedichloroplatinum(II)-induced DNA interstrand cross-link removal by 7-ethyl-10-hydroxy-camptothecin in HST-1 human squamous-carcinoma cells
12. CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer
13. Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer
14. Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer
15. Phase II study of irinotecan plus cisplatin in patients with advanced non-small cell lung cancer
16. Phase I clinical and pharmacologic study of weekly cisplatin combined with weekly irinotecan in patients with advanced solid tumors
17. Characterisation and clinical management of CPT-11 (irinotecan)-induced adverse events: The European perspective
18. Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea
19. How large should a Phase II trial of a new drug be?
20. Randomized Phase III trial comparing cisplatin/etoposide versus carboplatin/paclitaxel in advanced and metastatic non-small cell lung cancer
21. Cisplatin/etoposide vs. paclitaxel/cisplatin/G-CSF vs. paclitaxel/cisplafin in non-small-cell lung cancer
22. Randomized Phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer
23. A randomized trial of gemcitabine cisplatin (GP) versus mitomycin, ifosfamide and cisplatin (MIC) in advanced non-small cell lung cancer (NSCLC). A multicenter Phase Ill study
24. Phase III comparative study of high-dose cisplatin (HD-CIS) versus a combination of paclitaxel (TAX) and cisplatin (CIS) in patients with advanced non-small cell lung cancer (NSCLC)
25. Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer
26. A randomized phase III trial of paclitaxel plus carboplatin (PC) versus vinorelbine plus cisplatin (VC) in untreated advanced non-small cell lung cancer (NSCLC): A Southwest Oncology Group (SWOG) trial
27. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: Results of a European multicenter trial including 612 patients
28. Phase III study of cisplatin (C) with or without gemcitabine (G) in patients with advanced nonsmall cell lung cancer (NSCLC)
29. Randomized phase II trial of cisplatin (CDDP) vs. CDDP plus navelbine (NVB) in treatment of advanced non-small cell lung cancer (NSCLC): An update of a Southwest Oncology Group trial (SWOG-9308)
30. A Phase I study of irinotecan and infusional cisplatin for advanced non-small-cell lung cancer
31. Paclitaxel by either 1-hour or 24-hour infusion in combination with carboplatin in advanced non-small cell lung cancer: Preliminary results comparing sequential Phase II trials
32. Paclitaxel plus carboplatin in advanced non-small-cell lung cancer: A Phase II trial